DIRS.INFO The most relevant business & tech news

☆ Bladder cancer studies suggest new ways to treat the disease and improve survival
▼ + stars: | 2023-10-22 | by ( Jacqueline Howard | ) edition.cnn.com time to read: +9 min

This is one of several new studies exploring ways to improve how bladder cancer is treated. “Ever since I was in med school, a metastatic bladder cancer treatment was gemcitabine and platinum. Urothelial cancer is a type of bladder cancer that begins in the urothelial cells, which line the inside of the bladder. The drug became the first therapy targeting a genetic alteration to be approved by the FDA to treat patients with the most common type of bladder cancer, metastatic urothelial cancer. “These results support nivolumab plus cisplatin-based chemo as a new standard approach for the treatment of metastatic urothelial cancer.”

Persons: vedotin, hadn’t, ”, Thomas Powles, ” Powles, we’ve, —, Powles, Toni Choueiri, Dana, “, enfortumab, ” Choueiri, drugmaker Janssen, Dr, Sanjay Gupta, nivolumab, Matthew Galsky Organizations: CNN, Society for Medical Oncology, University of London, Barts Cancer, US, Inc, Astellas Pharma, Merck, Co, Food and Drug Administration, FDA, EMA, Lank, Genitourinary Oncology, Farber Cancer Institute, ESMO, New England, of Medicine, University of Texas, Anderson Cancer Center, US Food and Drug Administration, National Library of Medicine, CNN Health, Bristol Myers Squibb, Ono Pharmaceutical Company, Cancer, The Tisch Cancer Institute Locations: Madrid, United Kingdom, United States, Europe, Mount Sinai

☆ AstraZeneca shares fall as abstract for lung cancer trial data disappoints
▼ + stars: | 2023-10-18 | by ( ) www.reuters.com time to read: 1 min

A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble/File Photo Acquire Licensing RightsOct 18 (Reuters) - Shares in AstraZeneca (AZN.L) fell more than 4% on Wednesday after the publication of an abstract on its experimental precision drug's use in lung cancer in a late-stage trial disappointed some analysts. The abstract was published ahead the European Society for Medical Oncology's (ESMO) congress that kicks off in Madrid on Friday. By 1219 GMT, AstraZeneca shares were dwon 3.7% in London, while the broader STOXX Health Care (.SXDP)index was off 1%. Reporting by Danilo Masoni and Maggie FickOur Standards: The Thomson Reuters Trust Principles.

Persons: Phil Noble, Danilo Masoni, Maggie Fick Organizations: AstraZeneca, REUTERS, European Society for Medical, Thomson Locations: Macclesfield, Britain, Madrid, London

☆ AstraZeneca shares fall as lung cancer drug trial data abstract disappoints
▼ + stars: | 2023-10-18 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Phil Noble/File Photo Acquire Licensing RightsOct 18 (Reuters) - Shares in AstraZeneca (AZN.L) fell more than 4% on Wednesday after a data abstract on its experimental precision drug's use in lung cancer patients in a late-stage trial disappointed some analysts. Fernandez added that progression-free survival in lung cancer patients came in below expectations. Barclays analyst Emily Field also said in a note that safety looked better than expected for lung cancer patients and the data abstracts were "collectively positive" for AstraZeneca. London-listed shares of AstraZeneca were down 3.7% at 1219 GMT, while the broader STOXX Health Care (.SXDP) index was off 1%. Shares of AstraZeneca's Japanese partner Daiichi Sankyo (4568.T), which is jointly developing the cancer drug, closed 4.6% lower on Tuesday.

Persons: Phil Noble, datopotamab deruxtecan, Jefferies, Stephen Barker, Barker, Seamus Fernandez, Fernandez, Emily Field, GSK's, Danilo Masoni, Maggie Fick, Bhanvi, Shinjini Organizations: AstraZeneca, REUTERS, European Society for Medical, Friday, Guggeinheim, Barclays, AstraZeneca ., Thomson Locations: Macclesfield, Britain, Madrid, AstraZeneca . London, U.S, Milan, London, Bengaluru

Search resuls for: "Society for Medical Oncology"

3 mentions found